Welcome to our dedicated page for Icecure Medical news (Ticker: ICCM), a resource for investors and traders seeking the latest updates and insights on Icecure Medical stock.
IceCure Medical Ltd. develops and markets liquid-nitrogen-based cryoablation systems for minimally invasive tumor destruction. Its flagship ProSense® system is used for benign and cancerous lesions, with company updates centered on breast, kidney, bone and lung cancer indications and on markets where the device is cleared or approved, including the United States, Europe and Asia.
News about ICCM commonly covers ProSense commercialization, FDA-related breast cancer developments, post-market study activity, clinical evidence such as the ICESECRET kidney cancer study, medical-conference presentations, financial and operating results, and governance changes. The company’s updates also address physician training, reimbursement context and shareholder matters tied to its ordinary shares.
IceCure Medical (NASDAQ: ICCM) approved a 1-for-30 reverse share split of its ordinary shares to support regaining compliance with Nasdaq’s $1.00 minimum bid price requirement. Shares will begin trading on a split-adjusted basis on June 4, 2026 under the same ticker.
The reverse split, approved at a May 11, 2026 shareholder meeting, will reduce issued and outstanding shares from 84,201,034 to approximately 2,806,701, with no change to authorized share capital of 2.5 billion shares. Fractional shares will be rounded to the nearest whole share, and proportional adjustments will apply to options, warrants and equity plans.
IceCure Medical (NASDAQ:ICCM) reported new ProSense® cryoablation data presented at ECIO 2026. Final ICESECRET kidney cancer results showed 83.9% of patients recurrence-free at 4.0 years, rising to 89.4% for unifocal tumors ≤3 cm, with minimal impact on renal function and short 1.3-day average hospitalization.
Independent breast studies found no residual early-stage breast cancer at 6 and 12 months and 100% excellent cosmetic satisfaction. A fibroadenoma study showed 80.6% median volume reduction at 6 months and 92.9% at 12 months. An overbooked first-ever ECIO breast cryoablation course and prior FDA clearance in early-stage breast cancer support growing clinical interest.
IceCure (Nasdaq: ICCM) received a 180-day Nasdaq extension, until November 9, 2026, to regain compliance with the $1.00 minimum bid price requirement.
The company continues to meet all other Nasdaq Capital Market listing criteria, and its shares remain listed and trading under the symbol ICCM.
IceCure (Nasdaq: ICCM) reported Q1 2026 revenue of $911,000, up 26% year-over-year, driven by North America sales (+84%) and U.S. growth (+31%). Gross profit rose 35% to $295,000 with 32% margin.
Active U.S. ProSense® accounts increased 46% to 19, alongside positive breast and kidney cryoablation clinical data.
IceCure Medical (Nasdaq: ICCM) will report financial and operating results for the three months ended March 31, 2026 on Tuesday, May 12, 2026 before the Nasdaq opens. A conference call and live webcast to discuss results and corporate developments will be held at 11:00 a.m. EDT the same day.
Investors may join by phone (US: 1-888-407-2553; Israel/International: +972-3-918-0696) or via webcast at the company webcast link; a recording will be posted on the investor site.
IceCure (Nasdaq: ICCM) reported that preliminary, unaudited U.S. revenue for ProSense® systems and cryoprobes rose more than 30% in Q1 2026 vs Q1 2025.
The company highlighted commercial momentum after the FDA clearance in October 2025 for treating low-risk breast cancer in women aged 70+, participation and hands-on training at SBI 2026 (April 16–19, 2026), and an award-winning Massachusetts General Hospital cost study showing >50% cost reduction versus lumpectomy.
IceCure (Nasdaq: ICCM) priced a registered direct offering of 8,000,000 ordinary shares at $0.50 per share for gross proceeds of approximately $4.0 million. In a concurrent private placement the company will issue Series B and Series C warrants to purchase up to 8,000,000 shares each, exercisable at $0.55.
The Series B warrants expire five years after issuance; Series C warrants expire one year after issuance. Closing is expected on or about March 27, 2026. Net proceeds are intended for working capital and general corporate purposes. A.G.P./Alliance Global Partners is sole placement agent.
IceCure (Nasdaq: ICCM) reported positive top-line 5-year results from the ICESECRET trial of ProSense cryoablation for small renal masses (SRMs). At a median follow-up of four years, 83.9% of patients were recurrence-free; a subgroup with tumors ≤3 cm and no prior kidney cancer showed 89.4% recurrence-free.
The single-arm study enrolled 114 patients (138 lesions); 112 were evaluated. Detailed data will be presented at ECIO 2026 in Basel.
IceCure (NASDAQ: ICCM) appointed Meir Peleg as Chief Financial Officer, effective May 17, 2026, and plans to appoint Richard E. Fine, MD, as Medical Director for breast indications in Q2 2026. The company cites strong commercial momentum for ProSense® after FDA clearance in low‑risk breast cancer and an ASBrS recommendation.
IceCure initiated a search for a Chief Technology Officer and said VP of R&D Naum Muchnik will depart effective April 12, 2026. IceCure noted the FDA‑approved ChoICE post‑marketing study for ProSense®.
IceCure (Nasdaq: ICCM) reported record fourth-quarter sales of $1.3M and full-year 2025 revenue of $3.379M, driven by U.S. FDA clearance for ProSense® in low-risk breast cancer, new ASBrS guideline support, and expansion plans including a 30-site ChoICE post-marketing study.
Financials show gross profit $1.226M and narrowed net loss of $15.057M; cash and equivalents rose to $8.897M. Health Canada expansion application pending; patient enrollment for ChoICE expected H2 2026.